Suzhou Fushilai Pharmaceutical: Announcement on Using Partial Idle Own Funds to Invest in Securities
Suzhou Fushilai Pharmaceutical: Progress Announcement on Using Part of Idle Own Funds for Entrusted Wealth Management
Suzhou Fushilai Pharmaceutical: Legal Opinion of Shanghai Randy (Suzhou) Law Firm on the 2023 Annual General Meeting of Shareholders of Suzhou Fujilai Pharmaceutical Co., Ltd.
Suzhou Fushilai Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Suzhou Fushilai Pharmaceutical: Notice on Obtaining the Renewed “Pharmaceutical Production License”
Fujilai: Notice on Convening the Company's 2023 Annual General Meeting of Shareholders
Fujilai: 2023 Internal Control Self-Assessment Report
Fujilai: Articles of Association (revised in April 2024)
Fujilai: 2023 Financial Results Report
Fujilai: Special Report on Securities and Derivatives Investment in 2023
Fujilai: Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
Fujilai: Summary table on the use of non-operating capital by listed companies and other related capital transactions
Fujilai: 2023 Annual Financial Report
Fujilai: Notice on changing the scope of business of the company, revising the “Articles of Association”, and applying for commercial and commercial registration
Fujilai: Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders
Fujilai: Legal Opinion of Shanghai Randy (Suzhou) Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Suzhou Fujilai Pharmaceutical Co., Ltd.
Fujilai: Announcement on signing a three-party supervision agreement for fund-raising and cancelling some special fund-raising accounts
Fujilai: Announcement on Launching Foreign Exchange Derivatives Trading Business
Fujilai: Announcement on the Resignation of Supervisors and the By-election of Non-Employee Representative Supervisors
Fujilai: Notice on Convening the Company's Second Extraordinary General Meeting of Shareholders in 2024
No Data